SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, monocentric safety study to investigate conduction disturbances in patients receiving argatroban therapy.
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Argatroban (Primary)
- Indications Coronary arteriosclerosis
- Focus Therapeutic Use
- Acronyms SAICoDis
- Sponsors Mitsubishi Tanabe Pharma GmbH
- 03 Jul 2018 Status changed from recruiting to suspended.
- 24 Aug 2017 Planned End Date changed from 9 Jun 2017 to 9 Nov 2017.
- 17 Feb 2017 New trial record